Lentiviral-Mediated Astrocytic IGFBPL1 Expression via GFAP Promoter

Molecular Mechanism and Rationale

The lentiviral-mediated delivery of IGFBPL1 to astrocytes utilizes the neurotropic properties of pseudotyped lentiviral vectors and GFAP promoter specificity to target reactive astrocytes in neuroinflammatory conditions. Unlike AAV systems, lentiviruses integrate into the host genome, providing sustained long-term expression that is particularly advantageous for chronic neurodegenerative diseases. The VSV-G pseudotyped lentiviral particles bind to low-density lipoprotein receptor (LDLR) and phosphatidylserine receptors enriched on astrocytic endfeet at the blood-brain barrier. Following receptor-mediated endocytosis, the viral RNA undergoes reverse transcription and nuclear integration mediated by the viral integrase complex.

The GFAP promoter drives selective astrocytic expression through binding of astrocyte-specific transcription factors including STAT3, CREB, and AP-1, which are upregulated during reactive gliosis. Once expressed in astrocytes, IGFBPL1 modulates the astrocytic secretome by regulating IGF-1 bioavailability in the extracellular space, influencing neuronal survival and synaptic plasticity through paracrine signaling. IGFBPL1’s interaction with fibronectin and vitronectin in the astrocytic extracellular matrix facilitates glial scar formation and axonal regeneration. Additionally, astrocytic IGFBPL1 may modulate glutamate homeostasis by influencing GLT-1 and GLAST expression through IGF-1R/mTOR signaling cascades. The protein’s ability to sequester IGF-1 creates localized growth factor gradients that direct neuronal process extension and influence astrocyte-neuron metabolic coupling through regulation of glycogen metabolism and lactate shuttling pathways.

Preclinical Evidence

Lentiviral vectors pseudotyped with VSV-G have demonstrated efficient CNS transduction following intrathecal or intraventricular administration, with GFAP-driven expression achieving 70-85% astrocytic specificity in rodent models of neurodegeneration and neuroinflammation.